Notably, patients who underwent treatment exhibited a comparatively smaller increase in the size of brain lesions than untreated patients did.505 However, it is essential to acknowledge that in three out of eight patients, lesions and relapses exhibited exacerbation subsequent to vaccination.505 From a mechanistic standpoint, TCV elicits an antidiotypic T-cell response, leading to a gradual depletion of MBP-reactive T cells in all patients.506 Two more trials involving MS patients (49 and 54 patients, respectively) explored immune responses from vaccination with MBP-reactive T cells. The gene discussed is MBP; the disease is myeloid sarcoma.